论文部分内容阅读
CAR-T给无数的病患带来了生的希望,UCART的通用性有利于CAR-T治疗的标准化和平民化。成立于1999年的Cellectis是一家以细胞免疫疗法为技术手段的法国公司,拥有同种异源的CAR-T(Chimeric Antigen Receptor T-Cell Immunotherapy,嵌合抗原受体T细胞免疫疗法)技术平台。该平台可以改造单个供体的T细胞,并用于多个不同的患者。Cellectis让细胞疗法的适用性得以扩展到一个人群,而不仅仅局限于单个个体,从而能够实现工业化大规模生产,成为CAR-T领域的一匹黑马。2014年,
CAR-T brings hope to innumerable patients and the versatility of UCART facilitates the standardization and civilization of CAR-T treatment. Founded in 1999, Cellectis is a French company that uses cell-based immunotherapy as its technology. It owns the all-purpose CAR-T (Chimeric Antigen Receptor T-Cell Immunotherapy) technology platform. The platform can transform single donor T cells and be used in many different patients. Cellectis became a dark horse in the CAR-T space by extending the applicability of cellular therapies to a population rather than just individual individuals, enabling industrial mass production. Year 2014,